The global cell counting market size was estimated at USD 5,477.9 million in 2016 and is anticipated to grow at a CAGR of 7.8% during the forecast period. The rise in prevalence of chronic diseases that require next-generation therapeutics is the high impact rendering driver. This upsurge has resulted in extensive research activities that require advanced cell counting instruments. Some of these diseases include cancer, leukemia, HIV, and Alzheimer’s, which drive clinical urgency to develop drugs that possess greater potency.